This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 1, 2012 /PRNewswire/ --
Hagens Berman today announced that it is investigating Accretive Health Inc. (NYSE: AH) ("Accretive Health") following the release of a report by the
Minnesota Attorney General questioning certain practices used by the company.
Investors who purchased or otherwise acquired shares of Accretive Health common stock between
March 2, 2011 and
April 24, 2012 (the "Class Period"), and who suffered losses are encouraged to contact
Hagens Berman Partner Reed Kathrein. Mr. Kathrein is leading
Hagens Berman's investigation and can be reached at (510) 725-3000. Investors may also contact the firm via email at
AH@hbsslaw.com or by visiting
Jan. 19, 2012,
Minnesota's Attorney General filed a lawsuit alleging that Accretive Health violated privacy laws following the theft of a laptop containing patient data.
March 29, 2012, the company announced that in an effort to resolve the allegations and underlying issues, it would no longer collect debts for Fairview Health Services. The company announced that this shift would have a revenue impact "in the range of
$62 million to $68 million, or approximately 6% of the company's expected 2012 revenue."
Following the announcement, the share price of Accretive Health common stock fell nearly 19 percent.
The stock price fell again on
April 25, 2012, this time nearly 41 percent, following the
April 24, 2012 release of a report by the
Minnesota Attorney General which outlined a number of aggressive practices used by Accretive Health, including stationing debt collectors in emergency rooms.
Hagens Berman's investigation centers around claims that Accretive Health may have failed to disclose material information to investors regarding these allegations during the Class Period. The firm is investigating whether failure to disclose information may have caused the stock price to trade at an artificially high price during the class period.
"We are trying to determine whether Accretive Health knew about violations of privacy laws, but tried to conceal that information from investors," said Mr. Kathrein. "If the company tried to sweep these issues under the rug so as not to damage the share price, investors are entitled to compensation for their losses."